Invesaro

Stocks Comparison

Bristol Myers Squibb vs Pfizer: revenue, profit, margins and growth compared

Bristol Myers Squibb brought in $48.2B of revenue in fiscal 2025, Pfizer $62.6B in fiscal 2025. Revenue changed by -0.2% at Bristol Myers Squibb and -1.6% at Pfizer on the year before, so Bristol Myers Squibb grew faster. Bristol Myers Squibb kept 14.6% of its revenue as net profit, Pfizer 12.4%. Free cash flow was $12.8B at Bristol Myers Squibb and $9.1B at Pfizer.

Side by side, latest fiscal year

BMYPFE
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$48.2B$62.6B
Revenue growth-0.2%-1.6%
Net income$7.1B$7.8B
Net margin14.6%12.4%
Free cash flow$12.8B$9.1B
Free cash flow margin26.7%14.5%
Earnings per share (diluted)$3.46$1.36
Cash$10.2B$1.1B
Debt$44.8B$64.6B
Price to earnings18.221.1
Market value$128.4B$163.4B
Dividend yield3.96%6.00%
Rank by revenue in sector#16 of 523 · Health care#13 of 523 · Health care

Over the years

Revenue
BMY FY2018: $22.6BBMY FY2019: $26.1BBMY FY2020: $42.5BBMY FY2021: $46.4BBMY FY2022: $46.2BBMY FY2023: $45BBMY FY2024: $48.3BBMY FY2025: $48.2BPFE FY2018: $40.8BPFE FY2019: $40.9BPFE FY2020: $41.7BPFE FY2021: $81.3BPFE FY2022: $101.2BPFE FY2023: $59.6BPFE FY2024: $63.6BPFE FY2025: $62.6BFY18FY19FY20FY21FY22FY23FY24FY25
BMY $48.2BPFE $62.6B
Net income
BMY FY2018: $4.9BBMY FY2019: $3.4BBMY FY2020: -$9BBMY FY2021: $7BBMY FY2022: $6.3BBMY FY2023: $8BBMY FY2024: -$8.9BBMY FY2025: $7.1BPFE FY2018: $11.2BPFE FY2019: $16BPFE FY2020: $9.2BPFE FY2021: $22BPFE FY2022: $31.4BPFE FY2023: $2.1BPFE FY2024: $8BPFE FY2025: $7.8BFY18FY19FY20FY21FY22FY23FY24FY25
BMY $7.1BPFE $7.8B
Net margin
BMY FY2018: 21.8%BMY FY2019: 13.2%BMY FY2020: -21.2%BMY FY2021: 15.1%BMY FY2022: 13.7%BMY FY2023: 17.8%BMY FY2024: -18.5%BMY FY2025: 14.6%PFE FY2018: 27.3%PFE FY2019: 39.2%PFE FY2020: 22.0%PFE FY2021: 27.0%PFE FY2022: 31.0%PFE FY2023: 3.6%PFE FY2024: 12.6%PFE FY2025: 12.4%FY18FY19FY20FY21FY22FY23FY24FY25
BMY 14.6%PFE 12.4%
Revenue growth
BMY FY2019: +15.9%BMY FY2020: +62.6%BMY FY2021: +9.1%BMY FY2022: -0.5%BMY FY2023: -2.5%BMY FY2024: +7.3%BMY FY2025: -0.2%PFE FY2019: +0.2%PFE FY2020: +1.8%PFE FY2021: +95.2%PFE FY2022: +24.5%PFE FY2023: -41.1%PFE FY2024: +6.8%PFE FY2025: -1.6%FY19FY20FY21FY22FY23FY24FY25
BMY -0.2%PFE -1.6%
Free cash flow
BMY FY2018: $6.1BBMY FY2019: $7.4BBMY FY2020: $13.3BBMY FY2021: $15.2BBMY FY2022: $11.9BBMY FY2023: $12.7BBMY FY2024: $13.9BBMY FY2025: $12.8BPFE FY2018: $13.8BPFE FY2019: $10.5BPFE FY2020: $12.2BPFE FY2021: $29.9BPFE FY2022: $26BPFE FY2023: $4.8BPFE FY2024: $9.8BPFE FY2025: $9.1BFY18FY19FY20FY21FY22FY23FY24FY25
BMY $12.8BPFE $9.1B

Fiscal years as each company reports them; the two may end in different months.

Questions about Bristol Myers Squibb and Pfizer

Which is bigger by revenue, Bristol Myers Squibb or Pfizer?

Pfizer is bigger by revenue: $62.6B in fiscal 2025, against $48.2B for Bristol Myers Squibb in fiscal 2025.

Which keeps more of its revenue as profit, Bristol Myers Squibb or Pfizer?

Bristol Myers Squibb had a net margin of 14.6% in fiscal 2025; Pfizer had 12.4% in fiscal 2025.

Which grew revenue faster, Bristol Myers Squibb or Pfizer?

In their latest fiscal years revenue changed by -0.2% at Bristol Myers Squibb and -1.6% at Pfizer.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies